Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases such as alzheimer's disease and parkinson's

摘要

A method of treating amyloid, alpha-synuclein or NAC fibrillogenesis in an in vitro environment comprises administrating into the in vitro environment a proanthocyanidin selected from proanthocyanidin characterized by Formula I or Formula II and proanthocyanidin characterized by oligomeric combinations of Formula I and II wherein: n is 2 to 20 R1 and R2 are hydrogen or Hydroxy R3 is hydrogen, optionally substituted O-glycosyl, -C(O)-(optionally substituted aryl) or BC(O)-(optionally substituted heteroaryl); R4 is hydrogen, catechin, epicatechin, epifzelechin or galletes of catechin and epicatechin; The lines at the 2-, 3-, and 4- positions denote R and S configurations; The lines at the 4- and 8- positions in Formula I and the 4- and 6- positions in Formula II denote possible oligomer bonds between individual units. Pharmaceutical compositions can comprises the compounds described, for the treatment of an amyloid disease, or a disease characterized by alpha-synuclein or NAC fibrillogenesis. A method for isolating proanthocyanidin from a plant material comprise dissolving the plant material with ethanol or methanol, or then loading the ethanol/methanol-extracted plant material onto a LH20 column or silica gel column, and eluting the column with a series of increasing proportions of ethanol/methanol to elute the proanthocyanidins and then separating the proanthocyanidin in the extract by reverse phase HPLC and collecting and freeze drying the pure proanthocyanidin.